Nutraceutical Protocols:

Post-Herpetic Neuralgia (PHN)

Postherpetic neuralgia (PHN) is a chronic pain condition affecting nerve fibers. it occurs as a complication of shingles (herpes zoster). It manifests as burning, sharp, or shooting pain lasting 3+ months after the rash.

 

See:  

Acupuncture Introduction

  

Key to Links:

  • Grey text – handout
  • Red text – another page on this website
  • Blue text – Journal publication

Definitions and Terms Related to Pain

 

Nutraceutical Protocols:

Post-Herpetic Neuralgia (PHN)

Pathophysiological Rationale

Post-herpetic neuralgia represents a complex neuropathic pain syndrome with distinct mechanisms that provide multiple targets for nutraceutical intervention:

1. Peripheral mechanisms: Ectopic pacemaker activity in damaged sensory neurons, dorsal root ganglion (DRG) neuronal hyperexcitability, and loss of peripheral nerve fibers[1][2]

2. Spinal cord mechanisms: Astrocyte activation (more prominent than microglial activation in chronic PHN), NMDA receptor phosphorylation, and the “NO-Astrocyte-Cytokine-NMDAR-Neuron” pathway[3][4]

3. Central sensitization: Brush-evoked allodynia present in ~64% of PHN patients, associated with greater pain severity and psychological comorbidity[5]

4. Glial-mediated neuroinflammation: Spinal astrocytes drive chronic pain through IL-1β release and NMDA receptor sensitization; iNOS-derived nitric oxide mediates astrocyte activation[3][4]                                                                                                                                                        

RECOMMENDED NUTRACEUTICAL REGIMEN

Tier 1: Foundation Agents (For All   PHN Patients Taking Opioids)

These agents address both the neuropathic pain mechanisms and opioid tolerance/hyperalgesia:

  • Ultramicronized PEA: 600 mg twice daily. Meta-analyses confirm efficacy across nociceptive, neuropathic, and nociplastic pain types, with significant pain reduction at 6-8 weeks (SMD -0.97 for neuropathic pain specifically). PEA reduces mast cell degranulation, suppresses glial activation, and decreases TNF-α and NGF production—directly relevant to PHN pathophysiology. For opioid synergy, PEA delays tolerance to morphine, tramadol, and oxycodone while enhancing analgesia without requiring dose escalation.[7][8][9][10][11]
  • Magnesium: 200-400 mg elemental magnesium daily (glycinate or citrate). NMDA receptor antagonism is particularly relevant in PHN given the central role of NMDA receptor phosphorylation in spinal sensitization. Magnesium enhances opioid analgesia and reduces tolerance development by restoring the MOR-NMDAR complex.[12][13]
  • Melatonin: 5-10 mg at bedtime. Preclinical evidence demonstrates melatonin alleviates neuropathic pain via SIRT1 activation, improving mitochondrial dysfunction and reducing oxidative stress in DRG neurons. Melatonin inhibits the NF-κB/NLRP3 inflammasome pathway in spinal nerve ligation models. MT2 receptor agonism recruits mu-opioid receptors in the vlPAG, enhancing descending inhibition. However, a recent double-blind RCT (n=31) found no significant difference between melatonin (mean dose 11.9 mg/day) and placebo for neuropathic pain intensity, suggesting clinical translation may be limited.[14][15][16][17]
  • Vitamin B12 (Methylcobalamin): 1000-1500 mcg/day sublingual or 1 mg intramuscular weekly. Meta-analysis of 4 RCTs (383 participants) demonstrated significant pain reduction in PHN patients (NRS mean difference -4.01 points), improved quality of life, and decreased analgesic requirements. Methylcobalamin promotes nerve repair by increasing GAP-43 and SPRR1A expression in DRG and recovering non-myelinated neurons in affected skin.[18][19]

Tier 2: Neuroprotective and Anti-Neuroinflammatory Agents

  • Alpha-Lipoic Acid: 600 mg/day. Meta-analysis demonstrates efficacy for diabetic polyneuropathy symptoms (decreased stabbing pain, burning, paresthesia, numbness). ALA reduces oxidative stress, inhibits morphine tolerance by suppressing iNOS expression, and functions as a phase 2 inducer upregulating heme oxygenase-1. Both IV and oral routes demonstrate efficacy. However, a Cochrane review found ALA probably has little or no effect on neuropathy symptoms at 6 months, and a recent RCT showed no added benefit of combining ALA with pregabalin.[20][21][22][23][24]
  • Resveratrol: 150-500 mg/day. Attenuates morphine tolerance through AMPK activation suppressing microglial activation, SIRT1 upregulation in the spinal dorsal horn, and downregulation of NMDA receptor NR1/NR2B subunits. Preclinical evidence supports anti-neuroinflammatory effects via NF-κB and MAPK pathway suppression.[25]
  • Curcumin (bioavailable formulation): 500-1000 mg/day. Suppresses NF-κB and MAPK signaling pathways, reduces neuroinflammation, and inhibits CaMKIIα activity—preventing and reversing morphine tolerance. Preclinical studies demonstrate decreased mechanical allodynia and thermal hyperalgesia in neuropathic pain models.[25]

Tier 3: Adjunctive Agents (Based on Individual Presentation)

  • Omega-3 Fatty Acids (EPA/DHA): 2-3 g/day. Preclinical evidence supports anti-neuropathic pain effects through enhancement of neuron survival, activation of antinociceptive cannabinoid-1 and opioid receptors, and suppression of sodium channel currents. Produces additive antinociceptive effects with morphine and attenuates tolerance development.[25]
  • Vitamin D3: 2000-5000 IU/day (target serum 25(OH)D 40-60 ng/mL). Hypothesis paper suggests high-dose topical vitamin D may reduce glial inflammation and nitric oxide production in PHN. Vitamin D modulates opioid gene expression (Penk, Pdyn, Pomc), supporting descending pain modulation.[26]
  • NAC (N-Acetyl Cysteine): 600-1200 mg twice daily. Restores glutamate homeostasis via GLT-1 transporter upregulation, reduces oxidative stress, and may help prevent opioid dependence. Combined with ALA, effects on morphine tolerance are enhanced.

—

PROTOCOL SUMMARY TABLE

Agent

Dose

Primary Mechanism

in PHN

Opioid Synergy Mechanism

Evidence Level

References

Ultramicronized PEA

600 mg

2x/day

Mast cell/glial modulation, PPAR-α activation, NGF/TNF-α reduction

Delays opioid tolerance, enhances analgesia

Meta-analyses (moderate)

[1], [2], [3], [4]

Vitamin B12 (Methylcobalamin)

1000-1500

mcg/day

Nerve repair (GAP-43, SPRR1A), neuronal recovery

Indirect (nerve regeneration)

Meta-analysis (moderate)

[5], [6], [7]

Magnesium

200-400

mg/day

NMDA receptor antagonism, reduces central sensitization

Enhances opioid analgesia, reduces tolerance

Clinical trials

[8], [9]

Melatonin

5-10 mg

at night

SIRT1 activation, NLRP3 inhibition, mitochondrial protection

MT2-MOR recruitment in vlPAG

Preclinical strong; clinical negative

[10], [11], [12], [13]

Alpha-Lipoic

Acid

600 mg/day

Antioxidant,

iNOS suppression, HO-1 upregulation

Reduces morphine-induced oxidative stress

Mixed clinical evidence

[14], [15], [16], [17]

Resveratrol

150-500

mg/day

AMPK/SIRT1 activation, NMDA receptor modulation

Blocks microglial activation, attenuates tolerance

Preclinical

[18], [19]

Curcumin

500-1000 mg/day

NF-κB/MAPK suppression, CaMKIIα inhibition

Prevents/reverses morphine tolerance

Preclinical

[20], [21]

Omega-3

(EPA/DHA)

2-3 g/day

CB1/opioid receptor activation, sodium channel suppression

Additive antinociception, tolerance attenuation

Preclinical

[22]

[12][13][18][19][20][21][22][23][24][7][8][9][10][11][14][15][16][17][25]

—

IMPLEMENTATION STRATEGY

Phase 1 (Weeks 1-4): Foundation

  • Initiate ultramicronized PEA 600 mg twice daily
  • Start methylcobalamin 1000-1500 mcg/day (sublingual) or 1 mg IM weekly
  • Begin magnesium 200-400 mg daily (glycinate preferred for CNS penetration)
  • Add melatonin 5 mg at bedtime (increase to 10 mg if tolerated)

Phase 2 (Weeks 4-8): Neuroprotective Addition

  • Add alpha-lipoic acid 600 mg/day
  • Consider resveratrol 150-300 mg/day if inadequate response
  • Check vitamin D level; supplement to target 40-60 ng/mL

Phase 3 (Weeks 8-12): Optimization

  • Assess pain scores (NRS, DN4), opioid requirements
  • Add curcumin (bioavailable form) 500 mg/day if neuroinflammatory features persist
  • Consider omega-3 fatty acids 2 g/day for additional anti-inflammatory support
  • Adjust doses based on response and tolerability

Monitoring Parameters:

  • Pain intensity (NRS, VAS)
  • Neuropathic pain characteristics (DN4, LANSS)
  • Allodynia severity (brush-evoked pain)
  • Opioid dose requirements (track for stability or reduction)
  • Sleep quality (particularly with melatonin)
  • Functional status
  • Adverse effects (GI tolerability, sedation)

—

SPECIAL CONSIDERATIONS FOR PHN

Phenotype-Based Approach:

                                  

  • Allodynic PHN (~64% of patients): Central sensitization predominates. Prioritize NMDA-modulating agents (magnesium, resveratrol) and glial modulators (PEA, curcumin).[5]
  • Deafferentation PHN: Loss of sensory fibers predominates. Prioritize nerve-regenerating agents (methylcobalamin, ALC) and descending pathway enhancers (melatonin, vitamin D).
  • Mixed phenotype: Combination approach targeting both peripheral and central mechanisms.
  • Timing Considerations:
  • Acute zoster phase: Early initiation of antioxidants (ALA, NAC) and anti-inflammatory agents (PEA, curcumin) may theoretically reduce progression to PHN, though clinical trials are lacking.
  • Established PHN: Focus on central sensitization mechanisms and opioid synergy.

Integration with Standard Therapy:

Nutraceuticals should be considered adjunctive to guideline-recommended first-line therapies (gabapentin/pregabalin, TCAs, lidocaine patches, capsaicin). Evidence supports combination therapy over monotherapy for PHN.[42][43]

Glial-Targeting Rationale:

The document and current literature emphasize that spinal astrocyte activation (rather than microglia) is the primary driver of chronic PHN pain. The “NO-Astrocyte-Cytokine-NMDAR-Neuron” pathway represents a key therapeutic target.[3][4] Nutraceuticals targeting this pathway include:

  • PEA (reduces astrocyte activation)
  • Resveratrol (AMPK activation suppresses glial activation)
  • Curcumin (NF-κB inhibition reduces cytokine release)
  • ALA (iNOS suppression reduces NO production)

However, a systematic review of glial-modulating agents (minocycline, pentoxifylline, ibudilast) found no convincing evidence of clinical efficacy, highlighting the challenge of translating preclinical findings.[44]

Evidence Limitations:

Clinical trials specifically evaluating nutraceuticals in PHN patients on chronic opioids are lacking. The strongest clinical evidence exists for vitamin B12 (methylcobalamin) based on meta-analysis of RCTs in PHN. PEA has robust meta-analytic support for neuropathic pain broadly but limited PHN-specific data. Melatonin showed strong preclinical evidence but a recent RCT was negative. Alpha-lipoic acid evidence is mixed, with a Cochrane review suggesting limited benefit. Translation from preclinical findings requires appropriate caution.

References

  1. Neuropathic Pain: From Mechanisms to Treatment. Finnerup NB, Kuner R, Jensen TS. Physiological Reviews. 2021;101(1):259-301. doi:10.1152/physrev.00045.2019.
  2. Rethinking the Causes of Pain in Herpes Zoster and Postherpetic Neuralgia: The Ectopic Pacemaker Hypothesis. Devor M. Pain Reports. 2018;3(6):e702. doi:10.1097/PR9.0000000000000702.
  3. Spinal Astrocytic Activation Is Involved in a Virally-Induced Rat Model of Neuropathic Pain. Zhang GH, Lv MM, Wang S, et al. PloS One. 2011;6(9):e23059. doi:10.1371/journal.pone.0023059.
  4. Glial Contributions to Neuropathic Pain: Central and Peripheral Strategies in Postherpetic Neuralgia Pathogenesis and Therapeutics. Huang L, Huang Q, Zhang Z. The European Journal of Neuroscience. 2026;63(2):e70398. doi:10.1111/ejn.70398.
  5. Association Between Pain, Central Sensitization and Anxiety in Postherpetic Neuralgia. Schlereth T, Heiland A, Breimhorst M, et al. European Journal of Pain (London, England). 2015;19(2):193-201. doi:10.1002/ejp.537.
  6. Painful Sensory Neuropathy. Mendell JR, Sahenk Z. The New England Journal of Medicine. 2003;348(13):1243-55. doi:10.1056/NEJMcp022282.
  7. Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Viña I, López-Moreno M. Nutrition Reviews. 2025;83(7):e1604-e1618. doi:10.1093/nutrit/nuae203.
  8. Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-Analysis. Paladini A, Fusco M, Cenacchi T, et al. Pain Physician. 2016;19(2):11-24.
  9. Ultramicronized N-Palmitoylethanolamine Associated With Analgesics: Effects Against Persistent Pain. Nobili S, Micheli L, Lucarini E, et al. Pharmacology & Therapeutics. 2024;258:108649. doi:10.1016/j.pharmthera.2024.108649.
  10. Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence. Scuteri D, Guida F, Boccella S, et al. Pharmaceutics. 2022;14(8):1672. doi:10.3390/pharmaceutics14081672.
  11. The Endogenous Fatty Acid Amide, Palmitoylethanolamide, Has Anti-Allodynic and Anti-Hyperalgesic Effects in a Murine Model of Neuropathic Pain: Involvement of CB(1), TRPV1 and PPARgamma Receptors and Neurotrophic Factors. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. Pain. 2008;139(3):541-550. doi:10.1016/j.pain.2008.06.003.
  12. Complex Regional Pain Syndrome. Goebel A. The New England Journal of Medicine. 2025;393(23):2338-2348. doi:10.1056/NEJMcp2415752.
  13. Chronic Pain: An Update on Burden, Best Practices, and New Advances. Cohen SP, Vase L, Hooten WM. Lancet (London, England). 2021;397(10289):2082-2097. doi:10.1016/S0140-6736(21)00393-7.
  14. Melatonin Improves Mitochondrial Dysfunction and Attenuates Neuropathic Pain by Regulating SIRT1 in Dorsal Root Ganglions. Zeng Y, Fang Q, Chen J, et al. Neuroscience. 2023;534:29-40. doi:10.1016/j.neuroscience.2023.10.005.
  15. Melatonin for Neuropathic Pain: A Double-Blind, Placebo-Controlled, Randomized, Crossover Trial. Gilron I, Elkerdawy H, Tu D, et al. Pain. 2025;:00006396-990000000-00905. doi:10.1097/j.pain.0000000000003651.
  16. The Anti-Inflammatory and Analgesic Effects of Intraperitoneal Melatonin After Spinal Nerve Ligation Are Mediated by Inhibition of the NF-κB/NLRP3 Inflammasome Signaling Pathway. Wang YH, Tang YR, Gao X, et al. Brain Research Bulletin. 2021;169:156-166. doi:10.1016/j.brainresbull.2021.01.015.
  17. Targeting Melatonin MT2 Receptors: A Novel Pharmacological Avenue for Inflammatory and Neuropathic Pain. Posa L, De Gregorio D, Gobbi G, Comai S. Current Medicinal Chemistry. 2018;25(32):3866-3882. doi:10.2174/0929867324666170209104926.
  18. Vitamin B12 for Herpetic Neuralgia: A Meta-Analysis of Randomised Controlled Trials. Wang JY, Wu YH, Liu SJ, Lin YS, Lu PH. Complementary Therapies in Medicine. 2018;41:277-282. doi:10.1016/j.ctim.2018.10.014.
  19. Combined Effect of Neurotropin® and Methylcobalamin on Postherpetic Neuralgia in Mice Infected With Herpes Simplex Virus Type-1. Andoh T, Kikukawa T, Kotani A, et al. Journal of Dermatological Science. 2024;113(3):138-147. doi:10.1016/j.jdermsci.2024.02.004.
  20. Evaluation of the Analgesic Effect of Ɑ-Lipoic Acid in Treating Pain Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cassanego G, Rodrigues P, De Freitas Bauermann L, Trevisan G. Pharmacological Research. 2022;177:106075. doi:10.1016/j.phrs.2022.106075.
  21. Alpha-Lipoic Acid as an Antioxidant Strategy for Managing Neuropathic Pain. Viana MDM, Lauria PSS, Lima AA, et al. Antioxidants (Basel, Switzerland). 2022;11(12):2420. doi:10.3390/antiox11122420.
  22. Alpha-Lipoic Acid for Diabetic Peripheral Neuropathy. Baicus C, Purcarea A, von Elm E, Delcea C, Furtunescu FL. The Cochrane Database of Systematic Reviews. 2024;1:CD012967. doi:10.1002/14651858.CD012967.pub2.
  23. Effectiveness of Alpha Lipoic Acid Supplementation on Biochemical, Clinical, and Inflammatory Parameters in Patients With Diabetic Polyneuropathy: A Systematic Review and Meta-Analysis. Salinas AV, Caroca TM, Santibáñez FP, et al. Diabetes & Metabolic Syndrome. 2026;20(2):103374. doi:10.1016/j.dsx.2026.103374.
  24. Randomized, Double-Blind, Controlled Trial of a Combination of Alpha-Lipoic Acid and Pregabalin for Neuropathic Pain: The PAIN-CARE Trial. Gilron I, Robb S, Tu D, et al. Pain. 2024;165(2):461-469. doi:10.1097/j.pain.0000000000003038.
  25. Bioactive Compounds for Neuropathic Pain: An Update on Preclinical Studies and Future Perspectives. Shen CL, Castro L, Fang CY, et al. The Journal of Nutritional Biochemistry. 2022;104:108979. doi:10.1016/j.jnutbio.2022.108979.
  26. Post Herpetic Neuralgia, Schwann Cell Activation and Vitamin D. Bartley J. Medical Hypotheses. 2009;73(6):927-9. doi:10.1016/j.mehy.2009.06.039.
  27. Nociplastic Pain: Towards an Understanding of Prevalent Pain Conditions. Fitzcharles MA, Cohen SP, Clauw DJ, et al. Lancet (London, England). 2021;397(10289):2098-2110. doi:10.1016/S0140-6736(21)00392-5.
  28. FDA Orange Book. FDA Orange Book.
  29. Analgesic Efficacy of Melatonin: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials. Oh SN, Myung SK, Jho HJ. Journal of Clinical Medicine. 2020;9(5):E1553. doi:10.3390/jcm9051553.
  30. Analgesic Efficacy of Sleep-Promoting Pharmacotherapy in Patients With Chronic Pain: A Systematic Review and Meta-Analysis. Andersson E, Kander T, Werner MU, et al. Pain Reports. 2023;8(1):e1061. doi:10.1097/PR9.0000000000001061.
  31. Melatonin Is a Potential Novel Analgesic Agent for Osteoarthritis: Evidence From Cohort Studies in Humans and Preclinical Research in Rats. Li H, Zhou B, Wu J, et al. Journal of Pineal Research. 2024;76(2):e12945. doi:10.1111/jpi.12945.
  32. Efficacy of Curcumin and Boswellia for Knee Osteoarthritis: Systematic Review and Meta-Analysis. Bannuru RR, Osani MC, Al-Eid F, Wang C. Seminars in Arthritis and Rheumatism. 2018;48(3):416-429. doi:10.1016/j.semarthrit.2018.03.001.
  33. The Efficacy of Curcumin in Relieving Osteoarthritis: A Meta-Analysis of Meta-Analyses. Bideshki MV, Jourabchi-Ghadim N, Radkhah N, et al. Phytotherapy Research : PTR. 2024;38(6):2875-2891. doi:10.1002/ptr.8153.
  34. Curcuma as an Anti-Inflammatory Component in Treating Osteoarthritis. Koroljević ZD, Jordan K, Ivković J, Bender DV, Perić P. Rheumatology International. 2023;43(4):589-616. doi:10.1007/s00296-022-05244-8.
  35. Evaluating the Efficacy and Safety of Curcuma Longa, Boswellia Serrata, and Their Mixed Formulation in Treating Knee Osteoarthritis: A Systematic Review and Network Meta-Analysis. Inprasit C, Bunyamahote S, Boonpattharatthiti K, et al. Complementary Therapies in Medicine. 2025;:103256. doi:10.1016/j.ctim.2025.103256.
  36. The Role of Nutraceuticals in Osteoarthritis Prevention and Treatment: Focus on N-3 PUFAs. Oppedisano F, Bulotta RM, Maiuolo J, et al. Oxidative Medicine and Cellular Longevity. 2021;2021:4878562. doi:10.1155/2021/4878562.
  37. N-3 Polyunsaturated Fatty Acids Alleviate the Progression of Obesity-Related Osteoarthritis and Protect Cartilage Through Inhibiting the HMGB1-RAGE/TLR4 Signaling Pathway. Xiong T, Huang S, Wang X, et al. International Immunopharmacology. 2024;128:111498. doi:10.1016/j.intimp.2024.111498.
  38. Oral Treatment With Alpha-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy: The SYDNEY 2 Trial. Ziegler D, Ametov A, Barinov A, et al. Diabetes Care. 2006;29(11):2365-70. doi:10.2337/dc06-1216.
  39. Dietary Supplements for Treating Osteoarthritis: A Systematic Review and Meta-Analysis. Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ. British Journal of Sports Medicine. 2018;52(3):167-175. doi:10.1136/bjsports-2016-097333.
  40. Does Vitamin D Improve Symptomatic and Structural Outcomes in Knee Osteoarthritis? A Systematic Review and Meta-Analysis. Zhao ZX, He Y, Peng LH, et al. Aging Clinical and Experimental Research. 2021;33(9):2393-2403. doi:10.1007/s40520-020-01778-8.
  41. Effect of Omega-3 on Painful Symptoms of Patients With Osteoarthritis of the Synovial Joints: Systematic Review and Meta-Analysis. Bahamondes MA, Valdés C, Moncada G. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2021;132(3):297-306. doi:10.1016/j.oooo.2021.01.020.
  42. Therapeutic Strategies for Postherpetic Neuralgia: Mechanisms, Treatments, and Perspectives. Tang J, Zhang Y, Liu C, Zeng A, Song L. Current Pain and Headache Reports. 2023;27(9):307-319. doi:10.1007/s11916-023-01146-x.
  43. Management of Herpes Zoster and Post-Herpetic Neuralgia. Gan EY, Tian EA, Tey HL. American Journal of Clinical Dermatology. 2013;14(2):77-85. doi:10.1007/s40257-013-0011-2.
  44. Glial-Modulating Agents for the Treatment of Pain: A Systematic Review. Gilron I, Xiao MZX, Carley M, et al. Pain. 2025;166(5):1030-1049. doi:10.1097/j.pain.0000000000003447.

Emphasis on Education

 

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

 

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

 

Should you wish more information regarding any of the subjects listed – or not listed –  here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

 

For more information, please contact Accurate Clinic.

 

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.

 

 

.